Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
METHADONE HYDROCHLORIDE (UNII: 229809935B) (METHADONE - UNII:UC6VBE7V1Z)
H.J. Harkins Company Inc.
METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE 5 mg
ORAL
PRESCRIPTION DRUG
- For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. - For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). - For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Note – Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of his/her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone. Methadone is contr
Each 5 mg Methadone Hydrochloride Tablet USP contains 5 mg methadone hydrochloride USP. It is available as a white to off-white, modified rectangle shaped convex tablet, one side debossed with a score between “57” and “55”; on the other side. Each 10 mg Methadone Hydrochloride Tablet USP contains 10 mg methadone hydrochloride USP. It is available as a white to off-white, modified rectangle shaped convex tablet, one side debossed with a score between “57” and “71”; on the other side. Dispense in a tight, light-resistant container (as defined in USP) with a child-resistant closure. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. COVIDIEN™ Mallinckrodt Mallinckrodt Inc., Hazelwood, MO 63042 USA. Rev 011309
Abbreviated New Drug Application
METHADONE HYDROCHLORIDE - METHADONE HYDROCHLORIDE TABLET H.J. HARKINS COMPANY INC. ---------- METHADONE HYDROCHLORIDE TABLETS USP 5 MG, 10 MG CII RX ONLY DEATHS, CARDIAC AND RESPIRATORY, HAVE BEEN REPORTED DURING INITIATION AND CONVERSION OF PAIN PATIENTS TO METHADONE TREATMENT FROM TREATMENT WITH OTHER OPIOID AGONISTS. IT IS CRITICAL TO UNDERSTAND THE PHARMACOKINETICS OF METHADONE WHEN CONVERTING PATIENTS FROM OTHER OPIOIDS (_SEE_ DOSAGE AND ADMINISTRATION). PARTICULAR VIGILANCE IS NECESSARY DURING TREATMENT INITIATION, DURING CONVERSION FROM ONE OPIOID TO ANOTHER, AND DURING DOSE TITRATION. RESPIRATORY DEPRESSION IS THE CHIEF HAZARD ASSOCIATED WITH METHADONE HYDROCHLORIDE ADMINISTRATION. METHADONE'S PEAK RESPIRATORY DEPRESSANT EFFECTS TYPICALLY OCCUR LATER, AND PERSIST LONGER THAN ITS PEAK ANALGESIC EFFECTS, PARTICULARLY IN THE EARLY DOSING PERIOD. THESE CHARACTERISTICS CAN CONTRIBUTE TO CASES OF IATROGENIC OVERDOSE, PARTICULARLY DURING TREATMENT INITIATION AND DOSE TITRATION. IN ADDITION, CASES OF QT INTERVAL PROLONGATION AND SERIOUS ARRHYTHMIA (TORSADES DE POINTES) HAVE BEEN OBSERVED DURING TREATMENT WITH METHADONE. MOST CASES INVOLVE PATIENTS BEING TREATED FOR PAIN WITH LARGE, MULTIPLE DAILY DOSES OF METHADONE, ALTHOUGH CASES HAVE BEEN REPORTED IN PATIENTS RECEIVING DOSES COMMONLY USED FOR MAINTENANCE TREATMENT OF OPIOID ADDICTION. METHADONE TREATMENT FOR ANALGESIC THERAPY IN PATIENTS WITH ACUTE OR CHRONIC PAIN SHOULD ONLY BE INITIATED IF THE POTENTIAL ANALGESIC OR PALLIATIVE CARE BENEFIT OF TREATMENT WITH METHADONE IS CONSIDERED AND OUTWEIGHS THE RISKS. CONDITIONS FOR DISTRIBUTION AND USE OF METHADONE PRODUCTS FOR THE TREATMENT OF OPIOID ADDICTION Code of Federal Regulations, Title 42, Sec 8 Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Adminis Lue koko asiakirja